[Transfusion management and immuno-hematological follow-up after allogeneic hematopoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Autor:	Xhaard A; AP-HP, hôpital Saint-Louis, service d'hématologie-greffe, 1, avenue Claude-Vellefaux, 75010 Paris, France. Electronic address: alienor.xhaard@aphp.fr., Bouton M; EFS Nouvelle-Aquitaine, site de Pessac Haut-Lévêque, avenue de Magellan, Pessac, France., Delugin L; EFS Bretagne, laboratoire immuno-hématologie érythrocytaire, rue Pierre-Jean-Gineste, 35011 Rennes cedex, France., Giraud C; CHU de Poitiers, service d'hématologie et de thérapie cellulaire, 2, rue de la Miletrie, 86021 Poitiers, France; Centre de soins, EFS NVAQ, site de Poitiers, laboratoire de thérapie cellulaire, 350, avenue Jacques-Cœur, BP 482, 86012 Poitiers cedex, France., Guyon A; EFS Bourgogne-Franche-Comté, 8, rue du Docteur Jean-François-Xavier-Girod, 25000 Besançon, France., Giroux-Lathuile C; EFS Rhône-Alpes, 29, avenue du maquis du Grésivaudan, 38700 La Tronche, France., Hajjout K; Centre régional de transfusion sanguine de Rabat, Rabat, Maroc., Nicolas P; EFS Grand-Est, 10, rue Spielmann, 67000 Strasbourg, France., Peyrard T; EFS Île-de-France, CNRGS, 75011 Paris, France., Ratie V; EFS Bourgogne-Franche-Comté, 8, rue du Docteur Jean-François-Xavier-Girod, 25000 Besançon, France., Boisnard A; AP-HP, hôpital Necker, service d'hématologie adulte, 151, rue de Sèvres, 75015 Paris, France., Capelle L; CHU de Lille, service hématologie pédiatrique, Lille, France., Godin S; CHU de Lille, service hématologie pédiatrique, Lille, France., Traineau R; EFS Île-de-France, La Plaine Saint-Denis, France., Yacoub-Agha I; Université de Lille, CHU de Lille, Infinite, Inserm U1286, 59000 Lille, France., Leprêtre AC; EFS site Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.
Jazyk:	francouzština
Zdroj:	Bulletin du cancer [Bull Cancer] 2024 Feb; Vol. 111 (2S), pp. S78-S83. Date of Electronic Publication: 2023 Apr 11.
DOI:	10.1016/j.bulcan.2023.03.004
Abstrakt:	The French High Authority of Health (HAS) and National Drug Safety (ANSM) agencies recommendations issued in 2014, the French General Direction of Health (DGS) instruction published in November 2021, the French National Blood Bank (EFS) guidelines and the data available in the literature globally define "good transfusion practices" but provide little information about the immuno-hematological and transfusion management of patients who have received an allogeneic hematopoietic stem transplantation (allo-HCT). The aim of this workshop was to harmonize these practices in situations for which there are currently no recommendations. In order to anticipate possible transfusion issues after allo-HCT, we recommend performing, before the transplantation, an extended red blood cell phenotyping of the donor and a detection of HLA alloimmunization in the recipient. We recommend to systematically perform for minor ABO mismatches: a direct antiglobulin test between D8 and D20, and for major ABO mismatches; a titration of anti-A/anti-B antibodies and an erythrocyte chimerism at D100. At one-year post-transplant, we recommend carrying out an erythrocyte chimerism to allow, if necessary, the update of transfusion counselling (RH phenotype, irradiation of packed red blood cells). (Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu